Document:

Exhibit 10.1

 

INDEMNIFICATION ESCROW AGREEMENT

 

THIS INDEMNIFICATION ESCROW AGREEMENT (this
“Agreement”) dated as of January 28, 2021 is entered into by and among EZGO Technologies Ltd (the “Company”),
ViewTrade Securities, Inc. (the “Underwriter”), and Pearlman Law Group LLP (the “Escrow Agent”).

 

WITNESSETH:

 

WHEREAS, the Company is offering (the “Offering”)
on a firm commitment basis 2,800,000 ordinary shares of the Company, par value $0.001 (plus up to 420,000 ordinary shares that
the underwriters in the Offering have the option to purchase and such further ordinary shares as may be registered pursuant to
Rule 462), at an offering price of $4.00 per share;

 

WHEREAS, the Company and the Underwriter
expect that the Offering will close on or before the close of business on January 28, 2021 (the “Closing Date”);

 

WHEREAS, upon the closing of the Offering,
the Company has agreed to deposit an aggregate amount of Five Hundred Thousand Dollars ($500,000) (the “Escrowed Funds”)
from the proceeds of the Offering to be received by the Company with the Escrow Agent in an interest bearing escrow account, to
be held, invested and disbursed by the Escrow Agent pursuant to the terms and conditions of this Agreement; and

 

WHEREAS, the Escrow Agent is willing to
hold the Escrowed Funds and Investment Gain Funds (as such term is defined in Section 3(d)(v) below) in escrow pursuant to and
subject to the terms and conditions of this Agreement.

 

NOW, THEREFORE, in consideration of the
mutual promises herein contained and intending to be legally bound hereby, the parties hereto hereby agree as follows:

 

1. Appointment
of Escrow Agent. The Company and the Underwriter hereby appoint the Escrow Agent as escrow agent in accordance with the
terms and subject to the conditions set forth herein and the Escrow Agent hereby accepts such appointment.

 

2. Delivery of
the Escrowed Funds. Upon the closing of the Offering, the Escrowed Funds shall be delivered on behalf of the Company to
the Escrow Agent, as escrow agent, into an interest bearing escrow account maintained by the Escrow Agent (the “Escrow
Account”) by wire transfer in accordance with the wire transfer instructions set forth on Schedule A hereto. Such Escrow
Account shall bear interest at such rates as provided from time to time by the bank account in which the Escrow Funds are deposited.
In no event shall the aggregate amount of Escrowed Funds delivered to the Escrow Account be less than Five Hundred Thousand Dollars
($500,000).

 

    1

     

    

 

3. Escrow Agent
to Hold and Disburse the Escrowed Funds and Investment Gain Funds. The Escrow Agent will retain the Escrowed Funds and
Investment Gain Funds in an escrow account and disburse the Escrowed Funds and Investment Gain Funds pursuant to the terms of this
Agreement, as follows:

 

a. The
Escrowed Funds shall be held by the Escrow Agent for the purpose of satisfying the initial $500,000 of the indemnification obligations
of the Company, with respect to the Escrowed Funds, pursuant to Section 2 of the Underwriting Agreement dated January 25, 2021
by and between the Company and the Underwriter (the “Underwriting Agreement”), for a period of 12 months from
the closing of the Offering. Disbursement of such Escrowed Funds and Investment Gain Funds shall be determined by an independent
third-party trustee (who shall have the requisite experience determining indemnification claims), to be chosen by mutual written
consent of the Company and the Underwriter. If the Company and the Underwriter are unable to agree on such trustee within 30 days
upon a written claim for indemnification by the Underwriter, such trustee shall be a single arbitrator (with the requisite experience
in determining indemnification claims) selected by the American Arbitration Association’s Florida office.

 

b. Notwithstanding
the last sentence of the prior paragraph, in the event that any litigation or proceeding arising out of any matter in connection
with the Offering in connection to the Underwriter acting in its capacity as underwriter (which matter would be covered by the
Company’s indemnification obligations under the Underwriting Agreement) within 12 months following the Closing Date and in
which the Company, the Underwriter, the Escrow Agent or the Escrowed Funds becomes the subject of such litigation or proceeding,
the Underwriter and the Company hereby authorize the Escrow Agent, at the Underwriter’s sole instruction upon Underwriter’s
written notice to the Escrow Agent if not otherwise so required, to release and deposit the Escrowed Funds with the clerk of the
court in which the litigation is pending for the purpose of indemnifying and defending the Underwriter in such litigation and proceeding,
and thereupon the Escrow Agent shall be relieved and discharged of any further responsibility with regard thereto to the extent
determined by any such court. The Company and the Underwriter further hereby authorize the Escrow Agent, if it receives conflicting
claims to any of the Escrowed Funds, is threatened with litigation in its capacity as escrow agent under this Agreement, or if
the Escrow Agent determines it is necessary to do so for any other reason relating to this Agreement or the Offering, to interplead
all interested parties in any court of competent jurisdiction and to deposit the Escrowed Funds with the clerk of that court and
thereupon the Escrow Agent shall be relieved and discharged of any further responsibility hereunder to the parties from which they
were received to the extent determined by such court.

 

c. In
all instances, if either (i) no claim for indemnity is made by the Underwriter during the 12-month period from the closing of the
Offering or (ii) it is finally determined that the Underwriter is not entitled to any disbursement (or any further disbursement,
as the case may be) of Escrowed Funds by the conclusion of the 12-month period from the closing of the Offering, the Escrow Agent
shall, upon joint written instruction from the Company and the Underwriter, disburse to the Company the full balance of the Escrowed
Funds then held by wire transfer of immediately available funds to an account designated by the Company.

 

    2

     

    

 

d. Upon
written instruction of the Company, with a copy to the Underwriter the Escrow Agent may invest the Escrowed Funds during the term
of the Agreement as follows:

 

i. The
Escrowed Funds may be invested in issuers listed on U.S. national securities exchanges; provided that (1) no investments may be
made in the Company’s securities; (2) no more than 20% of the Escrowed Funds may be invested in one issuer; (3) no more than
50% of the Escrowed Funds may be invested in issuers that have: (A) a market capitalization of less than $1.0 billion; (B) been
public for less than two years; and (C) less than $1.0 million in average daily volume for the 30 days preceding such investment.

 

ii. In
the event the aggregate value of the Escrowed Funds plus the Investment Gain Funds in the Escrow Account decreases to less than
81% of the original amount ($500,000) of Escrowed Funds (“Minimum Equity”) for more than 20 consecutive trading
days, the Company shall promptly (but no later than 10 calendar days following the 20 consecutive trading days following the decrease
of less than 81%) add funds to the Escrow Account to maintain the Minimum Equity.

 

iii. Upon
the Escrow Account reaching Minimum Equity, the Company may not open any additional positions until the Escrow Account is above
the Minimum Equity.

 

iv. Upon
request from the Company, the Escrow Agent shall establish a brokerage account in the Company’s name with a FINRA registered
broker-dealer chosen by the Company and reasonably satisfactory to the Underwriter (the “Escrow Broker”). All
proposed transactions will be submitted by the Company in writing to the Underwriter with a confirmation by the Company that such
transaction(s) meet the criteria set forth in Sections 3(d)(i)-(iii). The Underwriter will have two business days after receipt
to review the submission. Unless the Underwriter disagrees in writing that the transaction(s) meet the criteria set forth in Sections
3(d)(i)-(iii) prior to the end of the second business day after receipt of the written submission by the Company, the Company may
submit the transaction request to the Escrow Agent for submission to the Escrow Broker with a copy to the Underwriter. The Escrow
Agent shall instruct the Escrow Broker to submit confirmations of all transactions to the Escrow Agent, the Company and the Underwriter.

 

v. All
income derived from the investments pursuant to this Section 3(d) in excess of the Escrowed Funds (“Investment Gain Funds”)
shall be disbursed to the Company as set forth in Section 3(a) above, provided that to the extent Investment Gain Funds exceed
$50,000 in excess of the Minimum Equity, the Company shall be permitted to request a disbursement of such excess funds in an amount
of no less than $50,000 on March 31, June 30, September 30 or December 31 of any year during the term of this Agreement prior to
the 12 month period set forth in Section 3(a).

 

4. Exculpation and Indemnification
of Escrow Agent.

 

a. The
Escrow Agent shall have no duties or responsibilities other than those expressly set forth herein. The Escrow Agent shall have
no duty to enforce any obligation of any person to make any payment or delivery, or to direct or cause any payment or delivery
to be made other than as set forth herein, or to enforce any obligation of any person to perform any other act. The Escrow Agent
shall be under no liability to the other parties hereto or anyone else, by reason of any failure, on the part of any party hereto
or any maker, guarantor, endorser or other signatory of a document or any other person, to perform such person’s obligations
under any such document. Except for amendments to this Agreement referenced below, and except for written instructions given to
the Escrow Agent by the Company and the Underwriter relating to the Escrowed Funds, the Escrow Agent shall not be obligated to
recognize any agreement between or among any of the Company and the Underwriter, notwithstanding that references thereto may be
made herein and the Escrow Agent has knowledge thereof.

 

    3

     

    

 

b. The
Escrow Agent shall not be liable to the Company, the Underwriter, or to anyone else for any action taken or omitted by it, or any
action suffered by it to be taken or omitted, in good faith and acting upon any order, notice, demand, certificate, opinion or
advice of counsel (including counsel chosen by the Escrow Agent), statement, instrument, report, or other paper or document (not
only as to its due execution and the validity and effectiveness of its provisions, but also as to the truth and acceptability of
any information therein contained), which is reasonably believed by the Escrow Agent to be genuine and to be signed or presented
by the proper party or parties hereunder. The Escrow Agent shall not be bound by any of the terms thereof, unless evidenced by
written notice delivered to the Escrow Agent signed by the proper party or parties hereunder and, if the duties or rights of the
Escrow Agent are affected, unless it shall give its prior written consent thereto.

 

c. The
Escrow Agent shall not be responsible for the sufficiency or accuracy of the form, or of the execution, validity, value or genuineness
of, any document or property received, held or delivered to it hereunder, or of any signature or endorsement thereon, or for any
lack of endorsement thereon, or for any description therein; nor shall the Escrow Agent be responsible or liable to the Company,
the Underwriter, or to anyone else in any respect on account of the identity, authority or rights, of the person executing or delivering
or purporting to execute or deliver any document or property or this Agreement. Except as otherwise set forth herein, the Escrow
Agent shall have no responsibility with respect to the use or application of the Escrowed Funds pursuant to the provisions hereof.

 

d. The
Escrow Agent shall have the right to assume, in the absence of written notice to the contrary from the proper party or parties
hereunder, that a fact or an event, by reason of which an action would or might be taken by the Escrow Agent, does not exist or
has not occurred, without incurring liability to the Company, the Underwriter, or to anyone else for any action taken or omitted
to be taken or omitted, in good faith and in the exercise of its own best judgment, in reliance upon such assumption.

 

e. To
the extent that the Escrow Agent becomes liable for the payment of taxes, including withholding taxes, in respect of the Investment
Gain Funds, or any payment made hereunder, the Escrow Agent may pay such taxes from the Escrowed Funds; and the Escrow Agent may
withhold from any payment of the Escrowed Funds and Investment Gain Funds such amount as the Escrow Agent estimates to be sufficient
to provide for the payment of such taxes not yet paid, and may use the sum withheld for that purpose. The Escrow Agent shall be
indemnified and held harmless against any liability for taxes and for any penalties in respect of taxes, on such investment income
or payments in the manner provided in Section 4(f).

 

    4

     

    

 

f. The
Escrow Agent will be indemnified and held harmless by the Company and the Underwriter from and against all expenses, including
all counsel fees and disbursements, or loss suffered by the Escrow Agent in connection with any action, suit or proceeding involving
any claim, or in connection with any claim or demand, which in any way, directly or indirectly, arises out of or relates to this
Agreement, the services of the Escrow Agent hereunder, except for claims relating to gross negligence or reckless misconduct by
the Escrow Agent or breach of this Agreement by the Escrow Agent, or the monies or other property held by it hereunder. Promptly,
but no later than 10 business days, after the receipt by the Escrow Agent of notice of any demand or claim or the commencement
of any action, suit or proceeding, the Escrow Agent shall, if a claim in respect thereof is to be made by the Escrow Agent against
the Company, notify the Company in writing, but the failure by the Escrow Agent to give such notice shall not relieve the Company
from any liability which the Company may have to the Escrow Agent hereunder, unless the failure of the Escrow Agent to give such
notice prejudices or otherwise impairs the Company’s ability to defend any demand, claim, action, suit or proceeding. Notwithstanding
any obligation to make payments and deliveries hereunder, the Escrow Agent may retain and hold for such time as it deems necessary
such amount of monies or property as it shall, from time to time, reasonably deem sufficient to indemnify itself for any such loss
or expense.

 

g. For
purposes hereof, the term “expense or loss” shall include all amounts paid or payable to satisfy any claim, demand
or liability, or in settlement of any claim, demand, action, suit or proceeding settled with the express written consent of the
Escrow Agent, and all costs and expenses, including, but not limited to, counsel fees and disbursements, paid or incurred in investigating
or defending against any such claim, demand, action, suit or proceeding.

 

5. Indemnification by the Company
and the Underwriter. The indemnification provisions subject to this Agreement are set forth in Section 6 of the Underwriting
Agreement, which Section 6 shall be deemed to be a part of this Agreement.

 

6. Termination of Agreement and Resignation
of Escrow Agent.

 

a. This
Agreement shall terminate upon disbursement of all of the Escrowed Funds and Investment Gain Funds provided that the rights of
the Escrow Agent and the obligations of the Company and the Underwriter under Section 4 shall survive the termination hereof.

 

b. The
Escrow Agent may resign at any time and be discharged from its duties as Escrow Agent hereunder by giving the Company and the Underwriter
at least 15 business days’ written notice thereof (the “Notice Period”). As soon as practicable after its resignation,
the Escrow Agent shall, if it receives notice from the Company and the Underwriter within the Notice Period, turn over to a successor
escrow agent appointed by the Company and the Underwriter all Escrowed Funds and Investment Gain Funds (less such amount as the
Escrow Agent is entitled to continue to retain and hold in escrow pursuant to Section 4(f)) upon presentation of the document appointing
the new escrow agent and its acceptance thereof. If no new agent is so appointed within the Notice Period, the Escrow Agent shall
return the Escrowed Funds and Investment Gain Funds to the Company without interest or deduction.

 

7. Form of Payments by Escrow Agent.

 

a. Any
payments of the Escrowed Funds by the Escrow Agent pursuant to the terms of this Agreement shall be made by wire transfer of immediately
available funds unless directed to be made by check by the Underwriter and/or Company, as applicable.

 

b. All
amounts referred to herein are expressed in United States Dollars and all payments by the Escrow Agent shall be made in such dollars.

 

    5

     

    

 

8. Compensation. Escrow Agent
shall be entitled to $12,500 as compensation for its services rendered under this Agreement, which amount shall be delivered by
the Company to an account designated by the Escrow Agent on the same date when the Escrowed Funds are delivered into the Escrow
Account and which shall be deemed earned in full upon payment.

 

9. Notices. All notices,
demands, consents, requests, instructions and other communications to be given or delivered or permitted under or by reason of
the provisions of this Agreement or in connection with the transactions contemplated hereby shall be in writing and shall be deemed
to be delivered and received by the intended recipient as follows: (i) if personally delivered, on the business day of such delivery
(as evidenced by the receipt of the personal delivery service), (ii) if mailed certified or registered mail return receipt requested,
on the business day of such delivery (as evidenced by the signed certified mail card), (iii) if delivered by overnight courier
(with all charges having been prepaid), on the business day of such delivery (as evidenced by the receipt of the overnight courier
service of recognized standing), (iv) if delivered by facsimile transmission, on the business day of such delivery if sent by 6:00
p.m. in the time zone of the recipient, or if sent after that time, on the next succeeding business day (as evidenced by the printed
confirmation of delivery generated by the sending party’s telecopier machine), or (v) if delivered by email on the business
day of such delivery (as evidenced by delivery confirmation). If any notice, demand, consent, request, instruction or other communication
cannot be delivered because of a changed address of which no notice was given (in accordance with this Section 9), or the refusal
to accept same, the notice, demand, consent, request, instruction or other communication shall be deemed received on the second
business day the notice is sent (as evidenced by a sworn affidavit of the sender). All such notices, demands, consents, requests,
instructions and other communications will be sent to addresses or facsimile numbers as applicable set forth hereunder.

 

If to the Company,
to:

 

EZGO Technologies Ltd.

Building #A, Floor 2, Changzhou Institute of Dalian
University of Technology

Science and Education Town

Wujin District, Changzhou City

Jiangsu, China 213164

Attention: Jianhui Ye, Chief Executive Officer

Email: yejianhui@ez-go.com.cn

Facsimile: + 86 51983683805

 

with a copy to (which shall not constitute notice):

 

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas

New York, New York 10105

Attention: Richard I. Anslow, Esq. and Richard Baumann,
Esq.

Email: ranslow@egsllp.com and rbaumann@egsllp.com

Facsimile: (212) 370-7889

 

    6

     

    

 

If to the Representative,
to:

 

ViewTrade Securities,
Inc.

7280 West Palmetto
Park Road, Suite 310

Boca Raton, FL 33433

Attention: Doug Aguililla

Email: dougagui@viewtrade.com

Facsimile: (561) 620-0302

 

with a copy to
(which shall not constitute notice):

 

Loeb & Loeb LLP

21st Floor, CCB Tower

3 Connaught Road Central

Hong Kong SAR

Attention: Lawrence
S. Venick, Esq.

Email: lvenick@loeb.com

Facsimile: +852-3923-1100

 

If to the Escrow
Agent, to:

 

Pearlman Law Group
LLP

200 South Andrews
Avenue, Suite 901

Fort Lauderdale, FL
33301

Facsimile: (954) 755-2993

Attention: Brian Pearlman

Email: brian@pslawgroup.net

 

10. Further Assurances. From
time to time on and after the date hereof, the Company and the Underwriter shall deliver or cause to be delivered to the Escrow
Agent such further documents and instruments and shall do and cause to be done such further acts as the Escrow Agent shall reasonably
request (it being understood that the Escrow Agent shall have no obligation to make any such request) to carry out more effectively
the provisions and purposes of this Agreement, to evidence compliance herewith or to assure itself that it is protected in acting
hereunder.

 

11. Consent to Service of Process.
The Company, the Underwriter and the Escrow Agent hereby irrevocably consent to the jurisdiction of the courts of the State of
Florida and of any Federal court located in such state in connection with any action, suit or proceedings arising out of or relating
to this Agreement or any action taken or omitted hereunder, and waives personal service of any summons, complaint or other process
and agrees that the service thereof may be made by certified or registered mail directed to it at the address listed hereto.

 

12. Miscellaneous.

 

a. This
Agreement shall be construed without regard to any presumption or other rule requiring construction against the party causing such
instrument to be drafted. The terms “hereby,” “hereof,” “hereunder,” and any similar terms,
as used in this Agreement, refer to the Escrow Agreement in its entirety and not only to the particular portion of this Agreement
where the term is used. The word “person” shall mean any natural person, partnership, corporation, government and any
other form of business of legal entity. All words or terms used in this Agreement, regardless of the number or gender in which
they were used, shall be deemed to include any other number and any other gender as the context may require. This Agreement shall
not be admissible in evidence to construe the provisions of any prior agreement.

 

    7

     

    

 

b. This
Agreement and the rights and obligations hereunder of the Company and the Underwriter may not be assigned without the consent of
the Escrow Agent, other than by laws of descent or operation of law. This Agreement and the rights and obligations hereunder of
the Escrow Agent may be assigned by the Escrow Agent, with the prior consent of the Company. This Agreement shall be binding upon
and inure to the benefit of each party’s respective successors, heirs and permitted assigns. No other person shall acquire
or have any rights under or by virtue of this Agreement. This Agreement may not be changed orally or modified, amended or supplemented
without an express written agreement executed by the Escrow Agent, the Company and the Underwriter, which consent shall not be
unreasonably withheld. This Agreement is intended to be for the sole benefit of the parties hereto and their respective successors,
heirs and permitted assigns, and none of the provisions of this Agreement are intended to be, nor shall they be construed to be,
for the benefit of any third person.

 

c. This
Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Florida. The representations
and warranties contained in this Agreement shall survive the execution and delivery hereof and any investigations made by any party.
The headings in this Agreement are for purposes of reference only and shall not limit or otherwise affect any of the terms thereof.

 

13. Execution of Counterparts.
This Agreement may be executed in any number of counterparts, by facsimile or other form of electronic transmission, each of which
shall be deemed to be an original as of those whose signature appears thereon, and all of which shall together constitute one and
the same instrument. This Agreement shall become binding when one or more of the counterparts hereof, individually or taken together,
are signed by all parties hereto.

 

[SIGNATURE PAGE FOLLOWS]

 

    8

     

    

 

IN WITNESS WHEREOF, the parties have executed
and delivered this Agreement on the day and year first above written.

 

ESCROW AGENT:

 

PEARLMAN LAW GROUP LLP

 

	By:	/s/ Brian Pearlman	 
	Name:	Brian Pearlman	 
	Title:	Partner	 

 

COMPANY:

 

EZGO TECHNOLOGIES LTD.

 

	By:	/s/ Jianhui Ye	 
	Name:	Jianhui Ye	 
	Title:	Chief Executive Officer	 

 

UNDERWRITER:

 

VIEWTRADE SECURITIES, INC.

 

	By:	/s/ Douglas K. Aguililla 	 
	Name:	Douglas K. Aguililla	 
	Title:	Director, Investment Banking	 

 

 

[Signature Page to Indemnification Escrow
Agreement]

 

    

     

    

 

Schedule A

 

 

Schedule A-1Exhibit 10.2

   

  Execution Copy

   

  CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF
    PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

   

  License Agreement

   

  THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of June 30, 2019 (“Effective Date”) by and between
      DR/Decision Resources, LLC (“Company”), a Delaware corporation, and Medical Outcomes Research Analytics, LLC (“Client”), a Delaware limited liability company. Company and Client are hereinafter sometimes referred to
    individually as a “Party” and together as the “Parties”.

   

  In consideration of the mutual promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
    Parties, intending to be legally bound, agree as follows:

   

  		1.	PROVISION OF SERVICES AND DATA.

   

  1.1       Services. Subject to the terms and conditions of this Agreement, Company will provide to Client the products and/or
    services identified in the attached Exhibit A (the “Deliverables” or “Services”). For purposes of this Agreement, an “Affiliate” is defined to include a Party’s subsidiaries, parent companies, and any other entities
    controlled or under common control. All references to “Company” and “Client” and all rights and obligations thereof shall include any and all of its Affiliates, as applicable.

   

  1.2       Licensed Data. Client may receive Services and/or access to data products that are: (a) compiled, created, or generated
    using Company’s proprietary databases; (b) licensed to Company directly; (c) licensed to Client where Company acts in the capacity of a database licensee; (d) syndicated reports and analyses based on sales forces or data components; (e) customized
    research and reports; and/or (f) consulting or analytical services. These data products, together with all related Deliverables in whatever media provided, whether now known or hereinafter developed, and including any Company data derived therefrom
    (but excluding Derivative Works (as defined below)) shall be collectively referred to as the “Licensed Data.” Licensed Data shall (i) at all times during the Term meet the specifications set forth in Exhibit A; (ii) at all times during
    the Term include all data field content received by Company from original sources of Licensed Data without modification other than as required by Law and to QC (including with respect to field value normalization) and deduplicate (it being understood
    that any ETL process employed by Company will not otherwise reduce such original data field content) as set forth in the data layout illustrated in Exhibit A-Attachment A to this Agreement; (iii) as of the Effective Date, include all
    prescription and medical transaction data and all EMR Data (as defined below) available to Company to license to Company’s customers; and (iv) at all times during the Term, except with respect to Additional Licensed Data (as defined below) that Client
    elects not to license hereunder, include all prescription and medical transaction data and all EMR Data then-available to Company to license to Company’s customers, and in no event less than the prescription and medical transaction data and EMR Data
    licensed by Company to other parties licensing such data. Company grants to Client and its successors and assigns a non-transferable (except as expressly set forth herein), non-exclusive, non-sublicensable (except as expressly set forth herein),
    limited right and license to use such Licensed Data solely in accordance with this Agreement. All licenses described in this Agreement are subject to Client’s compliance with the terms and conditions of this Agreement and payment of any undisputed
    amounts due.

   

  1.3       Licensed Data Use and Restrictions. The Licensed Data shall be used, stored and/or accessed in accordance with all
    applicable Laws. In addition to the rights granted to Client under Section 1.2, Company grants to Client and its successors and assigns a perpetual, non-exclusive, transferable, sublicensable, worldwide, royalty-free, right and license to use, copy,
    distribute (publicly and otherwise), display (publicly and otherwise), perform (publicly and otherwise), transmit, store, maintain and prepare derivative works of Licensed Data as needed for Client (or its successors or assigns) to develop,
    commercialize and exploit aggregations, queries, reports, enhancements or improvements to the Licensed Data (collectively, “Derivative Works”) for the benefit of customers within the permitted markets as described in Exhibit A. Client
    may disclose Company Confidential Information (including Licensed Data) to consultants, contractors, partners or suppliers (each, a “Third Party”) solely for the purpose of such Third Parties performing services for or with Client within the
    permitted markets as described in Exhibit A; provided, however, that any such Third Party has entered into an agreement with Client that contains confidentiality terms and use restrictions consistent with the terms and conditions of this
    Agreement; provided, further, however, that in the event that such Third Party will have access to Licensed Data and such Third Party will provide services other than (or in addition to) outsourced information technology assistance (including ETL,
    deduplication,

   

  

  
  
    	 	Page
            1 of 14

          	 

  

  
     

  

  
    

  cleansing, etc.) or nationally-recognized cloud/hosted storage, such Third Party has further entered into a Company-approved third party data use
    agreement substantially in the form attached hereto as Exhibit C. Except as provided in this Section 1.3, the Licensed Data shall not be: (i) copied, sold, rented, leased, transferred, or disclosed to any party without Company’s prior written
    consent, which consent shall not be unreasonably withheld, conditioned or delayed; (ii) stored, accessed, or used outside the U.S. without Company’s prior written consent (excluding with respect to Client’s use of a nationally-recognized cloud/hosted
    storage platform (e.g., Amazon Web Services, Microsoft Azure, Google Cloud)); (iii) used to identify an individual patient or an individual’s relatives or household members (other than on a de-identified anonymized basis) or to identify Company as the
    source of Licensed Data to any pharmacy or hospital provider; (iv) reengineered, reverse engineered, mashed up, linked to, used or combined with other data that would result in the re-identification of or the identification of the original source of
    Licensed Data or be in violation of applicable Law; and/or (v) published, quoted, made or reproduced for advertising, promotional or public relations purposes, reproduced or placed in any data retrieval systems (excluding with respect to Client’s use
    of a nationally-recognized cloud/hosted storage platform (e.g., Amazon Web Services, Microsoft Azure, Google Cloud)); provided however, for the avoidance of doubt, none of the above restrictions with respect to Licensed Data shall in any way apply to
    or limit in any way the use of Derivative Works. Client shall use its commercially reasonable efforts to promptly notify Company in the event it becomes aware of any use or disclosure of the Licensed Data that is not in conformity with the provisions
    of this Section 1.3. In each case of disclosure to the persons or entities expressly permitted in this Agreement, Client shall remain responsible for such persons’ and entities’ compliance with the terms and conditions of this Agreement.

   

  1.4       Compliance. The Licensed Data shall be delivered to Client in de-identified format in compliance with applicable Laws. The
    Parties, including the Party’s personnel, shall comply with all applicable laws, rules, ordinances and regulations (collectively, “Law”) relating to or affecting this Agreement or the Services. Each Party shall have the right to monitor and
    periodically audit or inspect for compliance with Law and this Agreement subject to the following terms and conditions: (i) if a Party demonstrates a good faith belief that the other Party is in breach of its obligations hereunder (the “Auditing
      Party”), then the Auditing Party shall provide written notice to the other Party describing such alleged breach; provided, however, that Client acknowledges Company shall have the right to audit Client without demonstrating a good faith belief of
    breach to the extent necessary to comply with audit rights granted by Company to the original sources of Licensed Data; (ii) if such Party is unable to address the Auditing Party’s concerns to its reasonable satisfaction within fifteen (15) days of its
    receipt of such notice, then such Party shall make available for inspection by a nationally-recognized firm of independent accountants reasonably acceptable to such Party (such consent not to be unreasonably withheld, conditioned or delayed) (the “Auditor”)

    any and all materials relevant to the alleged breach. The Party subject to the audit shall provide reasonable assistance to the Auditor and the audit shall be conducted during regular business hours upon at least fifteen (15) days prior written notice
    (which notice shall specify the purpose and scope of the audit and the time period to be audited), at the expense of the Auditing Party (which shall include the reasonable costs and expenses of the other Party in connection with any such audit unless
    any breach is determined to have occurred), and shall occur no more often than once per year during the Term. Prior to receipt of any access or information from either Party, the Auditor must execute an appropriate confidentiality agreement with
    respect to Confidential Information, which confidentiality agreement shall include restrictions on the disclosure of any Confidential Information to any third party, including the Auditing Party. The Party subject to the audit shall have the right to
    receive a copy of any such report and to discuss the basis of the conclusions reached with the Auditor and the Auditing Party. In addition, if so required by Law, each Party shall cooperate with any regulatory agency or other governmental authority
    that exercises its right to review or audit such Party’s books and records relating to the obligations under this Agreement.

   

  1.5       Contingent Rights.

   

  1.5.1       General. Company’s ability to provide the Licensed Data may be contingent upon certain corresponding rights, titles,
    interests, and licenses obtained by Company from third parties remaining in full force and effect (“Contingent Rights”) during the Term (as defined below), which Company covenants to use its commercially reasonable efforts to maintain in full
    force and effect during the Term. Should certain Company rights, titles, interests, or licenses pertaining to the Licensed Data, or any component thereof, be cancelled, terminated, rescinded, or not renewed, Client’s rights to use the previously
    delivered Licensed Data shall continue automatically and shall not constitute a breach by Client of any of its obligations under this Agreement and Company shall indemnify and hold harmless Client and its Indemnitees (as defined below) from any third
    party claims with respect thereto. Company shall provide to Client written notice as promptly as practicable (but in no event less than thirty (30) days) upon becoming aware of any actual or threatened changes to the quantity or quality of Licensed
    Data Company is able to provide and/or Company’s ability to provide the Licensed Data as described in 1.2.

   

  
  
    	 	Page
            2 of 14

          	 

  

  
     

  

  
   

  1.5.2       Licensed Data Reductions. Notwithstanding any language to the contrary set forth in this Agreement, beginning on the first
    anniversary of the Effective Date, if (i) the total volume of Licensed Data that constitutes prescription or medical transactions (excluding EMR Data (as defined below)) for any contract year during the Term declines by more than ten percent (10%) from
    the Baseline Volumes (as defined below) set forth in Exhibit A (other than with respect to EMR Data), Company and Client agree to a reduction in the Base Fees (as defined below) for the applicable contract year consistent with the actual
    percentage decrease in total Licensed Data (i.e. a twelve percent (12%) decrease in total transactions will trigger a twelve percent (12%) decrease in the Base Fees for the applicable contract year, which shall be credited to Client within ninety (90)
    days of the end of the applicable contract year); and (ii) after the first anniversary of the Effective Date, (w) the total volume of Licensed Data that constitutes prescription or medical transactions (excluding EMR Data) for any contract year during
    the Term declines by more than twenty percent (20%) from the prior contract year, (x) the total volume of Licensed Data that constitutes prescription or medical transactions (excluding EMR Data) at anytime during the Term (calculated using the trailing
    six-month transaction volume annualized) is twenty-five percent (25%) less than the applicable Baseline Volume, (y) the total volume of Licensed Data that constitutes prescription data at any time during the Term (calculated using the trailing
    six-month prescription Licensed Data volume annualized) is twenty-five percent (25%) less than the Licensed Data that constitutes the Baseline Volume of prescription data, or (z) the total volume of Licensed Data that constitutes medical data at any
    time during the Term (calculated using the trailing six-month medical Licensed Data volume annualized) is twenty-five percent (25%) less than the Licensed Data that constitutes the Baseline Volume of medical data, Company and Client agree to negotiate
    a reduction in the Base Fees consistent with the value proposition change (it being understood that in no event shall such reduction be less than the reduction in Licensed Data relative to applicable Baseline Volume). If the parties cannot agree on a
    reduction in the Base Fees following such good faith negotiations, then Client may terminate the Agreement upon thirty (30) days’ written notice to Company and shall receive a pro rata refund for Base Fees paid with respect to any period of Licensed
    Data deficiency prior thereto.

   

  1.5.3       Additional Licensed Data. Company acknowledges that Licensed Data in excess of that available as of the Effective Date (“Additional

      Licensed Data”) will be included in the license granted hereunder to the extent Company licenses additional prescription and medical transaction data or EMR Data during the Term (and Company has the right to license such data to Company’s
    customers), and agrees to provide to Client written notice as promptly as practicable of any increase in the total volume of Licensed Data relative to the Effective Date that constitutes prescription or medical transactions (excluding EMR Data) greater
    than five percent (5%) (calculated using the trailing six-month Licensed Data volume annualized). In the event that the volume of Additional Licensed Data (calculated using the trailing six-month Licensed Data volume annualized) including prescription
    or medical transactions (excluding EMR Data) constitutes more than ten percent (10%) of the total volume of like-kind (i.e., switch and/or clearinghouse-sourced medical and pharmacy transaction claims data) Licensed Data as of the Effective Date,
    Client shall have the option (with respect to the Additional Licensed Data that increases the total volume of Licensed Data ten percent (10%) or more above the Baseline Volume) as to whether to include or exclude such Additional Licensed Data within
    the Licensed Data licensed hereunder. To the extent Client elects to include such Additional Licensed Data, the Base Fees shall be increased consistent with the actual percentage increase in total Licensed Data (i.e. a twelve percent (12%) increase in
    total transactions will trigger a twelve percent (12%) increase in the Base Fees for such period that such Additional Licensed Data is included within the Licensed Data).

   

  		2.	FEES AND PAYMENT.

   

  2.1       Medical and Prescription Licensed Data Fee. Company will invoice Client pursuant to the terms set forth in Exhibit B.
    Except as set forth in Exhibit B, Client shall pay to Company (or an identified Company Affiliate) the fee amount set forth in Exhibit B for all Licensed Data that constitutes medical or prescription data (the “Base Fees” and,
    collectively with the Revenue Share Fees (as defined below), the “Fees”). Except as set forth in Exhibit B, undisputed Fees shall be paid within forty-five (45) days from the date of an invoice.

   

  2.2       EMR Data Revenue Share.

   

  2.2.1       Reporting. Within ten (10) business days after the end of each calendar quarter (“Quarter”) during the Term, Client
    shall provide to Company a system-generated report (each, a “Quarterly Report”), setting forth the revenue actually received by Client and recognized in accordance with then-applicable revenue recognition principles under GAAP for all Derivative
    Works utilizing electronic medical record or electronic medical record data (collectively, the “EMR Data”) (as provided as part of the Licensed Data) sold or licensed by Client to Client’s customers during the applicable Quarter

   

  

  
  
    	 	Page
            3 of 14

          	 

  

  
     

  

  
    

  (“Qualifying Revenue”), as the same may be adjusted for any Qualifying Revenue subsequently returned or credited to Client’s customers in
    Client’s reasonable discretion following a bona fide dispute with respect to the Derivative Works utilizing EMR Data.

   

  2.2.2       Fees and Payment Terms. In addition to the Base Fees, Client shall pay to Company [***] of the Qualifying Revenue set forth
    in each Quarterly Report (the “Revenue Share Fees”), subject to subsequent adjustment as described above. Company shall invoice Client for the Revenue Share Fees within ten (10) business days after its receipt of the Quarterly Report for such
    preceding Quarter.

   

  3.         TERM AND TERMINATION. The term of this Agreement will begin on the Effective Date and will continue through June 29, 2022 (the “Initial
      Term”), provided that Client shall have the sole right and option to extend the Term for each of three (3) successive two-year renewal periods upon delivery to Company of written notice not less than 30 days’ prior to the expiration of the then
    current Term (each such renewal period, a “Renewal Term” and collectively with the Initial Term, the “Term”). Either Party may terminate this Agreement for a material breach by the other Party upon thirty (30) days written notice
    specifying in detail the nature of the breach, unless such breach is cured within the thirty (30) day period; provided, however, for the avoidance of doubt and without limitation, Company’s failure to deliver the Deliverables timely in accordance with
    the schedule set forth in Exhibit A (other than any failure to deliver that results from Company’s loss of Contingent Rights that is remedied under Section 1.5 of this Agreement), and Client’s failure to provide payment of undisputed Fees in
    accordance with the schedule set forth in Exhibit B shall each constitute a material breach of this Agreement that requires cure within five (5) business days of written notice. A Party’s right to terminate in accordance with this Section 3
    shall be in addition to all available remedies, including a Party’s right to seek equitable relief pursuant to Section 8.6. Upon termination of this Agreement, for any reason, Client must immediately cease all uses of and destroy any and all Licensed
    Data provided to Client by Company; provided, however, that Client may retain (i) Licensed Data contained in an archived computer system back-up in accordance with security and/or disaster recovery procedures or in latent data, including deleted files
    and other non-logical data types such as memory dumps, swap files, temporary files, printer spool files and metadata that are not generally retrievable or accessible without the use of specialized tools and techniques, subject in each case to the
    destruction of such Licensed Data in due course and the inaccessibility of such Licensed Data for commercial purposes; and (ii) elements of Licensed Data incorporated into Derivative Works in accordance with the terms and conditions of this Agreement.
    For the avoidance of doubt, nothing in this Section 3 shall affect Client’s rights to Derivative Works.

   

  4.         INTELLECTUAL PROPERTY. Client acknowledges and agrees that all Licensed Data and/or Deliverables are the Intellectual Property of Company
    and/or Company’s data suppliers, may contain unpublished material and Confidential Information (as defined below), and are protected by copyright and/or other intellectual property Laws. Company acknowledges and agrees that, as between Company and
    Client, all Derivative Works, except to the extent of any Licensed Data contained therein, are the Intellectual Property of Client, may contain unpublished material and Confidential Information (as defined below), and are protected by copyright and/or
    other intellectual property Laws.

   

  5.         CONFIDENTIALITY. Each Party shall hold all confidential and proprietary information supplied to it by the other Party (the “Confidential
      Information”) in connection with this Agreement and relating to the business of such Party in confidence using the same degree of care used by the receiving Party to protect the receiving Party’s own confidential information (and in any event not
    less than a reasonable degree of care) and not disclose to third parties without the express written consent of the other Party. This confidentiality provision does not apply to any information: (i) available in the public domain through no fault of
    the receiving Party; (ii) independently developed by or on behalf of the receiving Party without reference to any Confidential Information of the disclosing Party; or (iii) disclosed to the receiving Party without restriction by a third party having a
    bona fide right to do so and not having an obligation of confidence with respect to such information. Nothing in this Agreement shall restrict a Party from disclosing any Confidential Information where the production of any such Confidential
    Information is compelled under process or request by a court or administrative or law enforcement agency of competent jurisdiction, provided that in each case the producing Party shall provide written notice to the disclosing Party (to the extent
    legally permissible) and ensure that such Confidential Information is afforded the highest level of protection via any available mechanisms for the protection of confidential or proprietary materials. Each Party shall have the right to disclose
    Licensed Data or Confidential Information to its employees, officers, directors, representatives and Third Parties but only as reasonably necessary to facilitate the Party’s performance of Services and to the extent such recipient agrees to keep the
    Licensed Data or Confidential Information confidential. All Deliverables shall be considered part of the Company Confidential Information. Derivative Works, shall not constitute Company Confidential Information.

   

  
  
    	 	Page
            4 of 14

          	 

  

  
     

  

  
   

  6.         REPRESENTATIONS; WARRANTIES; DISCLAIMER. Each Party represents and warrants to the other Party that it has the full power and authority to
    enter into and perform its obligations under this Agreement and that this Agreement is binding upon and enforceable against such Party as set forth herein. Company represents and warrants that the Services and Licensed Data delivered to Client do not:
    (a) infringe the intellectual property rights of any third party; (b) violate any Law applicable to the Services or Licensed Data; or (c) contain any viruses, Trojan horses, worms, time bombs, cancelbots or other harmful computer programming routines
    that are designed to damage, or detrimentally interfere with any system. Each Party further represents and warrants that it shall use its commercially reasonable efforts to perform its obligations hereunder, in compliance with all applicable Laws and
    consistent with industry standards. Except as expressly provided herein, any data provided to Client, including the Licensed Data, is provided “as-is.” Without limiting the generality of the foregoing, to the extent that Company delivers to Client any
    Licensed Data containing payer-level data, then Client acknowledges that any “estimated payer amount” field provided by Company in such Licensed Data is not sufficiently accurate to represent the true payer price and accordingly, should only be used by
    Client directionally and not in any contract negotiations. OTHER THAN AS EXPRESSLY SET FORTH IN THIS AGREEMENT, COMPANY MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE SERVICES AND/OR THE COMPILATION OF
      THE LICENSED DATA, INFORMATION OR OTHER DELIVERABLES INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

   

  7.         INDEMNIFICATION; LIMITATION OF LIABILITY.

   

  7.1       Indemnification. Each Party shall indemnify, defend and hold harmless the other Party and its Affiliates, and their
    respective directors, officers, shareholders, employees, representatives, agents, attorneys, successors and assigns (the “Indemnitees”), from and against any and all alleged loss, damage or expense, claims, suits, or proceedings, including
    reasonable attorneys’ fees, asserted by any third party against any of the Indemnitees as a result of the indemnifying Party’s (or its agents and/or contractors) material breach of this Agreement, provided that the Party requesting an indemnity timely
    notifies the other Party of such claim. The indemnifying Party shall not be liable for nor be required to indemnify the other Party in regard to any injury, loss or damage to the extent that such injury, loss or damage is directly caused by any
    negligent act or omission or intentional wrongdoing by the indemnified Party or its contractors or agents.

   

  7.2       Limitations of Liability. Other than with respect to Exceptional Circumstances (as defined below) and each party’s
    indemnification obligations hereunder, in no event shall a Party be liable to the other Party for any indirect, incidental, special, exemplary, consequential or punitive damages resulting from the performance of its obligations pursuant to this
    Agreement, even if advised of the possibility of such damages, and regardless of the form in which any action is brought. Notwithstanding anything to the contrary in this Agreement, except with respect to a Party’s (i) breach of Section 5, (ii) gross
    negligence, (iii) willful misconduct or fraud (collectively, “Exceptional Circumstances”) and (iv) indemnification obligations hereunder, the maximum aggregate monetary liability of a Party in connection with the Services, the Agreement, and any
    act or omission related to the Services or Agreement, under any theory of law (including breach of contract, tort, strict liability, violation of law, and infringement) shall not exceed an amount equal to the Fees paid hereunder.

   

  8.         MISCELLANEOUS PROVISIONS.

   

  8.1       Notices. All notices, authorizations, and requests in connection with this Agreement must be in writing and will be deemed
    given: (a) on the day they are hand delivered directly to the individual designated by the receiving Party as set forth below; (b) on the day receipt is confirmed by a nationally-recognized express courier (postage prepaid; signature required) or the
    United States Post Office (postage prepaid, certified mail receipt requested); or (c) on the day of transmittal if sent by .pdf electronic format via electronic mail, provided that the recipient confirms such receipt within one (1) business day
    thereafter (and receiving Party shall use its commercially reasonable efforts to confirm such receipt). In each case, any notice must be addressed to the receiving Party as follows (or to such other address as specified upon proper notice):

   

  	
          

          If to Client:

        	 
	Electronic Notice:	mwygod@wygodco.com
	Written Notice:	Medical Outcomes Research Analytics, LLC
	 	C/O: Max Wygod
	 	443 Greenwich Street, Apt. 4C
	 	New York, New York 10013

   

  
  
    	 	Page
            5 of 14

          	 

  

  
     

  

  
   

  	
          If to Company:

        	 
	
          Electronic Notice:

        	
          generalcounsel@teamDRG.com

        
	
          Written Notice:

        	
          DR/Decision Resources, LLC

        
	 	
          Attn: General Counsel

        
	 	
          100 District Avenue, Suite 213

        
	 	
          Burlington, MA 01803

        

  

  

   

  

  8.2       Assignment. Neither Party may assign, sublicense, transfer or delegate this Agreement without the express prior written
    consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed; provided, however, that either Party may, without the prior consent of the other Party, assign sublicense, transfer or delegate this Agreement in whole or in
    part to one or more of its Affiliates or to the successor in interest to a Party pursuant to the acquisition of a majority of the equity interests or assets of such Party. Any attempted assignment of this Agreement not in compliance with this Section 8.2
    shall be null and void. Subject to the foregoing, this Agreement will inure to and bind all successors, permitted assigns, receivers and trustees of the respective Parties hereto.

   

  8.3       Governing Law; Waiver of Trial by Jury. This Agreement shall be construed in accordance with the Laws of the State of
    Delaware, without giving effect to any conflicts of Law principles that would apply the Laws of another jurisdiction. THE PARTIES WAIVE TRIAL BY JURY IN CONNECTION WITH ANY CLAIM, ACTION, OR SUIT ASSERTED, BROUGHT, OR ARISING UNDER THIS AGREEMENT.

   

  8.4       Entire Agreement; No Waiver; Construction. This Agreement, together with any applicable exhibits, schedules, addenda, or
    other documents attached hereto or incorporated herein, contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes all oral understandings, representations, prior discussions, and preliminary agreements.
    Any change, modification, or amendment of this Agreement must be in writing and signed by each Party. The failure of a Party to enforce, or the delay by a Party in enforcing, any of its rights under this Agreement will not be deemed to be a waiver or
    modification by such Party of any of its other rights. No waiver of any right, obligation, or remedy under this Agreement will be effective against either Party unless it is in writing and signed by the waiving Party. When used herein, the words
    “include” or “including” or their syntactical variants shall be deemed followed by the words “without limitation”.

   

  8.5       Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which
    together shall constitute one and the same instrument. A Party may execute this Agreement by fax or in electronic format, and a fax, .pdf, or other electronic signature of an authorized signatory of a Party will be deemed to be an original signature,
    will be valid and binding, and, upon delivery, will constitute due execution of this Agreement.

   

  8.6       Equitable Relief. Each Party acknowledges that a breach of this Agreement may irreparably harm the other Party, that the
    damages suffered by the non-breaching Party as a result of such breach will be difficult to ascertain, and that the non-breaching Party may not have an adequate remedy at law for such breach. Each Party agrees and consents that in the event of such
    breach, the non-breaching Party shall be entitled, without posting bond, in addition to all other rights and remedies to which it may be entitled to seek a decree of specific performance or an injunction requiring any such violation to be cured and
    enjoining all representatives of such Party involved from continuing the violation. The existence of any claim or cause of action that a breaching Party or any other party may have against the non-breaching Party shall not constitute a defense or bar
    the enforcement of this Section 8.6. Each Party acknowledges and agrees that the restrictions in this Section 8.6 are reasonable and necessary to protect the legitimate business interests of each Party. 

   

  IN WITNESS WHEREOF, the Parties to this Agreement have executed this Agreement by their duly authorized representatives as of the Effective Date, intending to
    be legally bound hereby.

   

  	
          

          Medical Outcomes Research Analytics, LLC

        	DR/Decision Resources, LLC

        
	 	 	 	 
	By:	/s/ Max Wygod	By:	/s/ Michael Weiss

        
	Name:	Max Wygod	Name:	Michael Weiss
	Title:	President	Title:	EVP and General Counsel

        
	Date:	June 30, 2019	Date:	June 30, 2019

   

  
  
    	 	Page
            6 of 14

          	 

  

  
     

  

  
   

  

  Exhibit A

   

  	Deliverable Name	Medical Outcomes Research Analytics, LLC - Weekly Prescription, Medical and EMR Data Product Deliverable
	Territory	United States
	Project Details	
          Company will develop a custom solution that will provide Client with a weekly unique and usable prescription and medical data
            product, referenced herein as Licensed Data, to be delivered on a weekly basis. The custom Licensed Data Deliverables will include the following specifications, which are subject to Company’s application of its HIPAA Statistical Certification
            redaction, and in accordance with Attached A to this Exhibit A, prior to delivery in order to ensure that the Deliverables comply with all applicable Laws when delivered:

           

          Prescription Data:

          •      Inclusion of all data items within all revenue cycle related transactions

          •      Inclusion of all Patients age 2+ and within continental United States

          •      Inclusion of all Practitioners

          •      Data from all available Pharmacy Types (Retail, Mail Order, Specialty) will be included in the

          deliverable

          •      Prescription data will represent all therapeutic classes, NDCs, Forms and Strengths

          •      Claim Status (Approved, Reversed, Rejection) of the prescription as of the point in time of the

          deliverable

          •      Patients will be de-identified and tokenized with a Client-supplied Token ID that will be unique for deliveries
            to Client

           

          Medical Data:

          •     Inclusion of data items with all revenue cycle related transactions

          •     Inclusion of all Patients age 2+ and within continental United States

          •      Medical data will represent all Medical Office, Hospital, and Clinic claims and remittances

          •      Medical data will represent all ICDs. CPTs. JCodes and VCodes

          •      Medical data will represent all Practitioners

          •      Patients will be de-identified and tokenized with a Client-supplied Token ID that will be unique for deliveries
            to Client

           

          EMR Data:

          •     Inclusion of all Patients age 2+ and within continental United States

          •      EMR data will represent all Medical Office, Hospital,. and Clinic Patient encounters

          •      EMR data will represent all ICDs. CPTs. JCodes and VCodes

          •      EMR data will represent all Practitioners

          •      Patients will be de-identified and tokenized with a Client-supplied Token ID that will be unique for deliveries
            to Client

           

          The deliverables set forth in this Exhibit A, shall only be used to create Derivative Works from the
              Licensed Data for the following Permitted Uses for [***] as well as consulting and service providers supporting the same:

          [***] 

        
	 	
           

          The deliverables set forth in this Exhibit A, shall only be used to create Derivative Works from the Licensed Data for the following
            Permitted Uses for [***] as well as consulting and service providers supporting the same:

           

          [***]

        

   

  
  
    	 	Page
            7 of 14

          	 

  

  
     

  

  
   

  	 	
          Actual Table Layouts represented in Exhibit A - Attachment A

        
	Delivery and Updates	
          Anticipated Start Date: June 30, 2019

           

          First Delivery Date:

          Retrospective history on or before June 30, 2019

          Prospective data on or before June 30, 2019

           

          Final Delivery Date

          •      On or before June 30. 2022 (for Initial Term)

          •      On or before June 30, 2024 (for Renewal Term 1)

          •      On or before June 30. 2026 (for Renewal Term 2)

          •      On or before June 30, 2028 (for Renewal Term 3)

           

          Delivery Details

          •      Deliverable to include files as described in Exhibit A - Attachment A along with control report per deliverable
            file, which files shall have been subject to Company’s commercially reasonable quality control processes, including normalization of field/data element definitions and field/data element values and deduplication

           

          Frequency of Delivery:

          •      Weekly

          •      Delivered within 10 calendar days after the close of the data week

           

          Delivery mode:

          •      Flat File

           

          Delivery Method:

          •      To ensure data security, Client prefers files to be transferred through Amazon S3. This requires the use of a 3rd
            party sFTP or cloud/hosted storage program that supports Amazon S3 as a host.

        
	Data Reporting Period and Baseline Volumes	
          Weekly Prescription Data Deliverable:

          First Deliverable will contain 60 months of Licensed Data from June 30, 2014-June 29, 2019, including no less than [***] pharmacy transactions consistent with the specifications set forth in this Exhibit A. Each subsequent Deliverable will be presented with the retrospective month of data in weekly deliverables.

           

          Weekly Medical and Remittance Data Deliverable:

          First deliverable will contain 60 months of data from June 30, 2014-June 29, 2019, including no less than [***] medical transactions consistent with the specifications set forth in this Exhibit A. Each subsequent deliverable will be presented with the retrospective month of data in weekly deliverables.

           

          Monthly EMR Data Deliverable:

          First deliverable will contain 60 months of data from June 30, 2014-June 29, 2019, including no less than [***] electronic medical record encounters consistent with the specifications set forth in this Exhibit A. Each subsequent deliverable will be presented with the retrospective month of data in monthly deliverables.

           

          The volumes set forth above are referred to herein individually as a “Baseline Volume” and collectively as “Baseline
              Volumes”; provided, however, that the Baseline Volume for EMR Data shall be [***] electronic medical record encounters.

        

   

  
  
    	 	Page
            8 of 14

          	 

  

  
     

    Exhibit A - Attachment A

     

    Medical Data

     

    [***]

     

  

  

  
    	 	Page 9 of 14

          	 

  

  
     

    EMR Data

     

    [***]

  

  

  

  
    	 	Page 10 of 14

          	 

  

  
     

    Prescription Data

     

    [***]

  

  

  

  
    	 	Page
            11 of 14

          	 

  

  
     

  

  
   

  EXHIBIT B

  FEES SCHEDULE

   

  LICENSED DATA FEES AND PAYMENT TERMS. Company will invoice Client the fees for Services and Deliverables as described in the Agreement, and Client will pay such
    fees within thirty (30) days for the invoice deemed “Receipt of this Signed Agreement” and forty-five (45) days following the invoicing of all other invoices. Client will use commercially reasonable efforts to submit in writing any questions or
    disputes with respect to Services or Deliverables and relating invoices promptly after its receipt of such Services, Deliverables and related invoices. In the event that an invoice for Deliverables is under dispute in good faith at the time an invoice
    for subsequent Deliverables is due, Company and Client shall negotiate in good faith to reduce the Fees due under such pending invoice proportionately until resolution of the amounts under dispute.

   

  NON-DELIVERY PENALTY. In the event that Company fails to provide Licensed Data with the specifications and on the schedule set forth in Exhibit A and
    does not cure such breach within seven (7) business days of its receipt of written notice from Client, then appropriate senior executives from Company and Client shall immediately engage in good faith negotiations in order (i) to understand the cause
    of such delay and the actions being taken by Company to remediate the delay and related timing and (ii) to determine an appropriate remedy for the failure, which may include payment to Client of a mutually agreed amount of monetary compensation until
    the earlier to occur of (i) such breach being cured and (ii) Client’s determination in its sole reasonable discretion that such monetary remedy is inadequate to address such breach and election to seek equitable relief pursuant to Section 8.6 of the
    Agreement. Client may elect to have any such amounts offset future Fees owed to Company under this Agreement or to issue an invoice for such amounts, which Company shall pay within forty-five (45) days. This non-delivery penalty is in addition to all
    available remedies, including Client’s right to terminate and to equitable relief in accordance with Sections 3 and 8.6 of the Agreement; provided, however, that this penalty shall not apply to the loss of Contingent Rights that are remediated in
    accordance with Client’s rights under Section 1.5.

   

  Unless otherwise stated, all fees must be paid in U.S. Dollars.

   

  The Base Fees and relating invoicing schedule are set forth below. The Revenue Share Fees shall be paid in accordance with Section 2.2 of the Agreement.

   

  Base Fees

   

  	Services	Annual Term	Total Cash Fee
	
          History

           

          Historical Data View May 31, 2014 - May 31, 2019

           

          [***]

        	June 30, 2014-June 29, 2019	$[***]
	
          Term Years 1, 2 and 3

           

          Weekly Prescription and Medical Licensed Data Deliverable with

          Client-Supplied Token ID:

          •      Weekly Deliverable

           

          [***]

        	
          June 30, 2019-June 29, 2020

           

        	$[***]
	
          June 30, 2020-June 29, 2021

           

        	$[***]
	
          June 30, 2021-June 29, 2022

           

        	$[***]
	 	TOTAL INITIAL TERM FEES	$[***]
	
          Renewal Term 1 (Years 4 and 5)

          Weekly Prescription and Medical Licensed Data Deliverable with

          Client-Supplied Token ID:

          •      Weekly Deliverable

           

          [***]

        	
           

          June 30, 2022 - June 29, 2023 

           

        	$[***]
	
           

          June 30, 2023 - June 29, 2024 

           

        	$[***]
	 	TOTAL
              RENEWAL TERM 1 FEES	$[***]

   

  
  
    	 	Page
            12 of 14

          	 

  

  
     

  

  
   

  	
          Renewal Term 2 (Years 6 and 7)

           

          Weekly Prescription and Medical Licensed Data Deliverable with

          Client-Supplied Token ID:

          •      Weekly Deliverable

           

          [***]

        	June 30, 2024-June
            29, 2025	$[***]
	
          

           

           

          June 30, 2025 - June 29, 2026

           

           

        	$[***]
	 	TOTAL RENEWAL TERM 2 FEES	$[***]
	
          Renewal Term 3 (Years 8 and 9)

           

          Weekly Prescription and Medical Licensed Data Deliverable with

          Client-Supplied Token ID:

          •      Weeklv Deliverable

           

          [***]

        	June 30, 2026-June 29, 2027	$[***]
	 	June 30, 2027-June 29, 2028	$[***]
	 	TOTAL RENEWAL TERM 3 FEES	$[***]
	 	 	 
	 	TOTAL TERM FEES (WITH RENEWALS)	$[***]

   

  INVOICING. All fees are quoted are exclusive of applicable taxes.

   

  	
          

          INVOICE #

        	INVOICE DATE/MILESTONE	INVOICE AMOUNT (USD)
	1	Upon Company’s Receipt of this Signed
            Agreement	$[***]
	2	1 Apr 20	$[***]
	3	1 Oct 20	$[***]
	4	1 Jan 21	$[***]
	5	1 Jun 21	$[***]
	6	1 Jan 22	$[***]
	 	
          INITIAL TERM INVOICE TOTAL AMOUNT

          (USD):

        	$[***]
	Renewal Term 1 (Years 4 and 5) 1	1 Jun 22	$[***]
	2	1 Jan 23	$[***]
	3	1 Jan 23	$[***]
	4	1Jan24	$[***]
	 	
          RENEWAL TERM 1 INVOICE TOTAL AMOUNT

          (USD)

        	$[***]
	Renewal Term 2 (Years 6 and 7) 1	1 Jun 24	$[***]
	2	1 Jan 25	$[***]
	3	1 Jun 25	$[***]
	4	1 Jan 26	$[***]
	 	
          RENEWAL TERM 2 INVOICE TOTAL AMOUNT

          (USD)

        	$[***]
	Renewal Term 3 (Years 8 and 9) 1	1 Jun 26	$[***]
	2	1 Jan 27	$[***]
	3	1 Jun 27	$[***]
	4	1 Jan 28	$[***]
	 	
          RENEWAL TERM 3 INVOICE TOTAL AMOUNT

          (USD)

        	$[***]

   

  
  
    	 	Page
            13 of 14

          	 

  

  
     

  

  
   

  EXHIBIT C

    FROM OF THIRD PARTY AGREEMENT

   

  Provided Separately

   

  
  
    	 	Page
            14 of 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]